search
Back to results

A First-In-Human SAD and MAD Study to Evaluate the Safety, Tolerability, PK and PD of SC Administered ALTB-268 in Healthy Volunteers

Primary Purpose

Healthy Volunteers

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
ALTB-268
Placebo
Sponsored by
AltruBio Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Healthy Volunteers

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Written Informed Consent and willingness to comply with the study restrictions. Sex: male or female volunteers. Age: 18 to 55 years, inclusive, at screening. Body mass index (BMI): 18.0 to 32.0 kg/m2, inclusive, at screening. Weight: 50 kg to 110 kg, inclusive, at screening. Healthy volunteers: Healthy status as defined by the absence of evidence of any clinically significant, in the opinion of the Investigator, active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead ECG, hematology, blood chemistry, serology, and urinalysis Exclusion Criteria: Males with female partners who are pregnant, lactating, or planning to become pregnant during this study or within 90 days after dosing of study drug. Use of any investigational drug or device within 30 days or five half-lives whichever is longer, of the first dose of study drug. Any disease which, in the opinion of the Investigator, poses an unacceptable risk to the volunteers. Clinically significant history of any drug sensitivity, drug allergy, or food allergy, as determined by the Investigator (such as anaphylaxis, hepatotoxicity, or treatment with steroids or epinephrine). Confirmatory circumstances would include treatment with epinephrine or in emergency department.

Sites / Locations

  • ICON Early Development ServicesRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

ALTB-268

Placebo

Arm Description

Subcutaneous dose in healthy volunteers

Subcutaneous dose in healthy volunteers

Outcomes

Primary Outcome Measures

Incidence of ALTB-268 Treatment-Emergent Adverse Events
Adverse events (AEs) - severity of the AEs will be graded using the most current version of the Common Terminology Criteria for AE (CTCAE) (V5.0) 5-point scale. The relationship between AEs and the study drug will be indicated as related or not related.

Secondary Outcome Measures

Pharmacokinetics of ALTB-268 AUC (PK) of sc administered ALTB-268 in healthy volunteers.
Including AUC0-t, AUC0-inf, AUC0-tau
Pharmacokinetics of ALTB-268 Cmax
Maximum plasma concentration
Pharmacokinetics of ALTB-268 tmax
Time to reach Cmax
Pharmacokinetics of ALTB-268 t1/2
Half life
Pharmacokinetics of ALTB-268 CL/F
Apparent clearance, calculated as dose/AUC0-inf
Pharmacokinetics of ALTB-268 Rac
The ratio of accumulation of a drug after repeated administration as compared to a single dose, PART B only

Full Information

First Posted
January 20, 2023
Last Updated
October 16, 2023
Sponsor
AltruBio Inc.
Collaborators
ICON plc
search

1. Study Identification

Unique Protocol Identification Number
NCT05723692
Brief Title
A First-In-Human SAD and MAD Study to Evaluate the Safety, Tolerability, PK and PD of SC Administered ALTB-268 in Healthy Volunteers
Official Title
A First-In-Human, Randomized, Double-Blind, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered ALTB-268 in Healthy Volunteers
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 17, 2023 (Actual)
Primary Completion Date
August 30, 2023 (Actual)
Study Completion Date
December 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AltruBio Inc.
Collaborators
ICON plc

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This study with ALTB-268 will determine the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of ALTB-268 in healthy volunteers.
Detailed Description
This is a Phase I, first-in-human, randomized, double-blind, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered ALTB-268 in healthy volunteers. Up to 40 and 24 healthy volunteers will be recruited in single and multiple ascending doses, respectively. The primary objective is to assess the safety and tolerability of subcutaneously (sc) administered ALTB-268 in healthy volunteers. The secondary objective is to assess the plasma pharmacokinetics of sc administered ALTB-268 in healthy volunteers. The exploratory objectives are to assess the pharmacodynamics and evaluate immunogenicity of sc administered ALTB-268 in healthy volunteers.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Healthy Volunteers

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Model Description
Study consists of 2 parts: Part A: a single ascending dose (SAD) and Part B: multiple ascending dose (MAD).
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
64 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
ALTB-268
Arm Type
Experimental
Arm Description
Subcutaneous dose in healthy volunteers
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Subcutaneous dose in healthy volunteers
Intervention Type
Biological
Intervention Name(s)
ALTB-268
Intervention Description
monoclonal antibody
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
formulation buffer
Primary Outcome Measure Information:
Title
Incidence of ALTB-268 Treatment-Emergent Adverse Events
Description
Adverse events (AEs) - severity of the AEs will be graded using the most current version of the Common Terminology Criteria for AE (CTCAE) (V5.0) 5-point scale. The relationship between AEs and the study drug will be indicated as related or not related.
Time Frame
through study completion, up to day 120 of the study
Secondary Outcome Measure Information:
Title
Pharmacokinetics of ALTB-268 AUC (PK) of sc administered ALTB-268 in healthy volunteers.
Description
Including AUC0-t, AUC0-inf, AUC0-tau
Time Frame
through study completion, up to day 120 of the study
Title
Pharmacokinetics of ALTB-268 Cmax
Description
Maximum plasma concentration
Time Frame
through study completion, up to day 120 of the study
Title
Pharmacokinetics of ALTB-268 tmax
Description
Time to reach Cmax
Time Frame
through study completion, up to day 120 of the study
Title
Pharmacokinetics of ALTB-268 t1/2
Description
Half life
Time Frame
through study completion, up to day 120 of the study
Title
Pharmacokinetics of ALTB-268 CL/F
Description
Apparent clearance, calculated as dose/AUC0-inf
Time Frame
through study completion, up to day 120 of the study
Title
Pharmacokinetics of ALTB-268 Rac
Description
The ratio of accumulation of a drug after repeated administration as compared to a single dose, PART B only
Time Frame
through study completion, up to day 120 of the study
Other Pre-specified Outcome Measures:
Title
Pharmacodynamics of ALTB-268 Receptor Occupancy
Description
Receptor Occupancy will be measured using a flow cytometry based method
Time Frame
through study completion, up to day 120 of the study
Title
Exploratory Immunophenotyping Lymphocyte subsets
Description
Lymphocyte subsets, T,B and NK cells will be assessed using a flow cytometry based method
Time Frame
through study completion, up to day 120 of the study
Title
Pharmacodynamics - change in target engagement biomarkers
Description
inhibition of cytokine release from ex-vivo stimulated T cells and the change of soluble (free) PSGL-1 molecule
Time Frame
through study completion, up to day 120 of the study

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Written Informed Consent and willingness to comply with the study restrictions. Sex: male or female volunteers. Age: 18 to 55 years, inclusive, at screening. Body mass index (BMI): 18.0 to 32.0 kg/m2, inclusive, at screening. Weight: 50 kg to 110 kg, inclusive, at screening. Healthy volunteers: Healthy status as defined by the absence of evidence of any clinically significant, in the opinion of the Investigator, active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead ECG, hematology, blood chemistry, serology, and urinalysis Exclusion Criteria: Males with female partners who are pregnant, lactating, or planning to become pregnant during this study or within 90 days after dosing of study drug. Use of any investigational drug or device within 30 days or five half-lives whichever is longer, of the first dose of study drug. Any disease which, in the opinion of the Investigator, poses an unacceptable risk to the volunteers. Clinically significant history of any drug sensitivity, drug allergy, or food allergy, as determined by the Investigator (such as anaphylaxis, hepatotoxicity, or treatment with steroids or epinephrine). Confirmatory circumstances would include treatment with epinephrine or in emergency department.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Simona Reed, PhD
Phone
714-215-0224
Email
simona.reed@altrubio.com
First Name & Middle Initial & Last Name or Official Title & Degree
Jesse W Hall, MD
Phone
8182925393
Email
jesse.hall@altrubio.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Daniel Dickerson, MD
Organizational Affiliation
ICON plc
Official's Role
Principal Investigator
Facility Information:
Facility Name
ICON Early Development Services
City
Lenexa
State/Province
Kansas
ZIP/Postal Code
66219
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dishae Smith
Phone
913-410-2862
Email
dishae.smith@iconplc.com
First Name & Middle Initial & Last Name & Degree
Daniel S Dickerson, MD, PhD

12. IPD Sharing Statement

Learn more about this trial

A First-In-Human SAD and MAD Study to Evaluate the Safety, Tolerability, PK and PD of SC Administered ALTB-268 in Healthy Volunteers

We'll reach out to this number within 24 hrs